组织多肽特异性抗原在原发性肝癌中的临床应用

摘要/Abstract

摘要： 目的探讨组织多肽特异性抗原(TPS)对原发性肝癌的临床应用价值,并与甲胎蛋白(AFP)进行比较。方法采用酶联免疫吸附法,分别测定85例原发性肝癌、19例肝转移癌、35例肝硬化、22例慢性肝炎和50例健康查体者血清TPS和AFP水平,并应用ROC曲线分析其对肝癌的诊断价值。结果 AFP对原发性肝癌的诊断价值高于TPS。肝细胞癌组AFP血清水平高于胆管癌组(P=0.037),但两组之间TPS血清水平无显著性差异(P=0.737)。TPS与肿瘤大小之间存在显著相关性(P=0.001),但与肿瘤数目、门脉癌栓、肝外转移、临床分期及病理分级均无显著相关性(P>0.05);AFP与肿瘤大小、门脉癌栓及病理分级之间存在显著相关性(P<0.05=)。结论单独检测TPS的血清水平对原发性肝癌未显示出比AFP更高的诊断价值,但对胆管癌的诊断具有一定的指导意义。血清TPS对原发性肝癌与肝转移癌、肝硬化及肝炎的鉴别能力较差,限制了其临床应用价值。

Abstract: Objective To evaluate the clinical value of serum tissue polypeptide specific antigen (TPS) for primary hepatic cancer in comparison with alpha-fetoprotein (AFP). Methods TPS and AFP were measured by enzyme-linked immunosorbent assay (ELISA) in 85 patients with primary hepatic cancer, 19 with metastatic hepatic cancer, 35 with liver cirrhosis, 22 with chronic hepatitis and 50 healthy control subjects. Results Serum AFP levels were elevated in patients with hepatocellular carcinoma in comparison with that in cholangiocarcinoma patients (P=0.037), but the difference was not significant (P=0.737). Serum TPS levels were significantly correlated with the tumor size (P=0.001), but not with the number of the tumors, portal invasion, extrahepatic metastasis, clinical stage or histological differentiation (P>0.05). A significant correlation was observed between AFP level and tumor size (P=0.028), portal invasion(P=0.005), and histological differentiation (P=0.000). Conclusion TPS alone offers no more clues than AFP for the diagnosis of primary hepatic cancer, though it can be helpful for the diagnosis of cholangiocarcinoma. It has only limited clinical utility as a marker for primary hepatic cancer.

中图分类号:

R730

黄达仁¹, 左强², 蔡红兵², 张军一², 季晨阳². 组织多肽特异性抗原在原发性肝癌中的临床应用[J]. 南方医科大学学报, 2005, 25(01): 89-92.

HUANG Da-ren¹, ZUO Qiang², CAI Hong-bing², ZHANG Jun-yi², JI Chen-yang². Clinical value of serum tissue polypeptide specific antigen detection for primary hepatic cancer[J]. Journal of Southern Medical University, 2005, 25(01): 89-92.

参考文献

[1] Deugnier Y, David V, Leray G, et al. Biological markers in hepatocellular carcinoma [J]. Ann Biol Clin, 1988, 46(1):85-8.
[2] Einarsson R, Rydlander L. Tissue polypeptide specific antigen(TPS) detects a specific epitope structure on human cytokeratin[J]. Anticancer Res, 1997, 17(4B): 3121-4.
[3] Madersbacher S, Gregor N, Theyer G, et al. TPS is a useful epithelial proliferation and tumor marker[J]. J Urol, 1992, 147(3): 911.
[4] Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue polypeptide-specific-antigen epitope and its relationship to human cytokeration 18 [J]. Eur J Biochem, 1996, 241(2):309-14.
[5] 郑航,何本夫,罗荣城.TPS、NSE和CEA联合检测对肺癌的诊断价值[J].第一军医大学学报,2003,23(2):165-7.Zheng H, He BF, Luo RC. Diagnostic value of combined detection ofTPS, NSE and CEA in lung cancer [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(2): 165-7.
[6] 郑航,何本夫,罗荣城,等.组织多肽特异性抗原在乳腺癌中的临床研究[J].第一军医大学学报,2003,23(8):823-5.Zheng H, He BF, Luo RC, et al. Clinical study of serum tissue polypeptide-specific antigen in breast cancer [J]. J First Mil Med Univ/Di Yi Jun Yi-Da Xue Xue Bao, 2003, 23(8): 823-5.
[7] 吴令英,孙建衡,王希霞,等.组织多肽抗原在卵巢癌诊断及监测中的应用[J].中华妇产科杂志,1998,33(2):92-4.Wu LY, Sun JH, Wang XX, et al. The clinical value of tissue polypeptide antigen in ovarian carcinoma [J]. Clin J Obstet Gynecol, 1998, 33(2): 92-4.
[8] Tu DG, Wang ST, Chang TT, et al. The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma[J]. Cancer, 1999, 85(5): 1039-43.
[9] Watanabe M, Chigusa M, Takahashi H, et al. High level of CA19-9,CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo [J]. In Vitro Cell Dev Biol Anim, 2000, 36(2): 104-9.
[10] Yao WJ, Chang TT, Wang ST, et al. Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma[J]. Oncology, 2001, 61 (1): 64-70.

[1]	陈智贤，孙爱民，陈勇，刘英，詹军芳，陈龙华，袁亚维. 放射敏感性、X线辐射剂量对鼻咽癌细胞miR-7表达的影响[J]. 南方医科大学学报, 2010, 30(08): 1810-1816.
[2]	刘刚，卢光琇. 湖南汉族人群CTLA4 基因+49G/A 多态性与乙肝感染和乙肝源性肝癌相关性的初步研究[J]. 南方医科大学学报, 2010, 30(08): 1838-1840.
[3]	李金龙1，蔡于琛，胡志明，高基民 . 去甲斑蝥素对肿瘤细胞DNA 复制起始蛋白Cdc6 的抑制作用[J]. 南方医科大学学报, 2010, 30(08): 1851-1853.
[4]	齐桓；李玉华；郑少斌； . 以沙门氏菌为载体的口服基因治疗对小鼠肿瘤的作用[J]. 南方医科大学学报, 2006, 26(12): 1738-1741.
[5]	王顺官；洪文松；蔡长青；. 胶片剂量分析系统及其在放疗验证中的应用[J]. 南方医科大学学报, 2006, 26(07): 1039-1040.
[6]	林骏；杨进城；谭丽；罗深秋； . 阻断PLC-γ1通路对TNF-α抑制胶质瘤细胞增殖并诱导其凋亡的影响[J]. 南方医科大学学报, 2006, 26(03): 266-269.
[7]	叶靖；许乙凯；刘岘；吕国士；. 链霉亲合素-DTPA-Gd经腹腔和静脉注射后对荷瘤裸鼠磁共振肿瘤靶向成像的强化效应(英文)[J]. 南方医科大学学报, 2006, 26(02): 139-143.
[8]	袁亚维¹, 孙爱民¹, 李传刚². KBV200细胞多药耐药与蛋白激酶C表达上调的关系[J]. 南方医科大学学报, 2005, 25(11): 1341-1343,1356.
[9]	徐本华¹, 韩露², 林少俊², Touboul E³. 立体定向放射外科治疗脑转移瘤预后因素分析[J]. 南方医科大学学报, 2005, 25(11): 1425-1428.
[10]	刘布骏, 顾菲. 风湿性疾病合并肿瘤26例临床分析[J]. 南方医科大学学报, 2005, 25(11): 1448-1449.
[11]	曲利娟, 丁彦青, 梁莉. 人大肠癌不同转移潜能细胞株SW620及SW480的差异蛋白质组分析[J]. 南方医科大学学报, 2005, 25(10): 1211-1215,1220.
[12]	刘昳, 叶峰, 邱根全, 章梅, 王锐, 何群英, 蔡云. 白术内酯Ⅰ对肿瘤恶病质患者细胞因子和肿瘤代谢因子的影响[J]. 南方医科大学学报, 2005, 25(10): 1308-1311.
[13]	黄宗海, 苏国强, 俞金龙, 厉周, 范应方, 周广军, 宋慧娟. 双自杀基因重组腺病毒对胃癌细胞及血管内皮细胞的体外特异性杀伤作用[J]. 南方医科大学学报, 2005, 25(08): 947-950.
[14]	冉立伟, 谭升顺, 王万卷, 邱实, 雷小兵, 曾惟惠. 全反式维A酸、阿维A和他扎罗汀对人黑色素瘤细胞A375凋亡和Bax/Bcl-2蛋白表达的影响及意义[J]. 南方医科大学学报, 2005, 25(08): 972-974,978.
[15]	钱新宇, 罗荣城, 李黎波, 廖旺军, 罗宇玲. Photofrin-Herceptin偶联物对肿瘤细胞株的体外杀伤效应[J]. 南方医科大学学报, 2005, 25(08): 975-978.